Project Grant R42DK130764

Award Date 9/23/21
Completion Date 7/31/24
Dollars Obligated $2.5M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
This Project Grant award of $3,740,270, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development and evaluation of a subnormothermic (room temperature) oxygenated perfusion platform for extended preservation of high-risk kidney grafts. The awardee, Biomedinnovations, Inc. (BMI), is collaborating with investigators at the Duke Ex Vivo Organ Lab...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $1,930,758 to Sylvatica Biotech Inc., a minority-owned small business, to develop enhanced supercooling techniques for extended non-freezing preservation of clinical-scale porcine and human donor livers. The key objectives are to: 1) explore strategies for longer duration, lower temperature supercooling using oil...
This Project Grant award of $134,852 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to develop a low-cost, non-destructive system called longitudinally detected electron paramagnetic resonance (LOD-EPR) to quantify and image iron oxide nanoparticles (IONPs) in cryopreserved rat kidneys. The goal is to optimize IONP perfusion, distribution, and radiofrequency heating parameters to improve...
The federal Project Grant award R01DK140070, in the amount of $700,619, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) program. The goal of this 4-year award is to study and control rhythmic nephron induction for kidney replacement tissues. The research aims to gain temporal control over rhythmic nephron formation in human induced pluripotent stem cell-derived kidney...
This $1,470,094 project grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) will fund research by New York University School of Medicine to optimize pre-implantation kidney transplant biopsy interpretation using artificial intelligence (AI) assistance. The key products and services to be delivered under this 5-year project include: Developing a comprehensive unbiased atlas of histopathology in pre-implantation deceased donor kidney biopsies using...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on enhancing the efficiency of generating human vasculature in a gene-edited pig. The $279,750 award, granted on May 25, 2025, aims to compare the grantee's proven approach using somatic cell nuclear transfer (SCNT) with an alternative approach using in vitro fertilization, zygote gene editing, and blastocyst complementation. The goal...
The National Institutes of Health Office of the Director awarded the University of Southern California a $2.9 million project grant under the Trans-NIH Research Support program (CFDA 93.310) to develop a synthetic kidney as a revolutionary solution to the shortage of kidneys available for transplantation. The three-year project will generate a transplantable synthetic kidney using stem cell and bioengineering technologies, then evaluate its growth, differentiation, vascularization and functional...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $746,895 to the Regents of the University of Minnesota to establish a non-human primate platform in genetically modified pigs. The goal is to engineer a humanized heart in a gene-edited pig that could serve as an alternative organ source for cardiac transplantation. The key products and services to be delivered...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...

PROTECTION OF DONOR KIDNEYS WITH SYNCHRONIZATION MODULATION ELECTRIC FIELD (SMEF) - THE GOALS OF THIS PHASE II APPLICATION: 1) DETERMINE THE TRANSLATIONAL SIGNIFICANCE OF THE I-SMEF (IMPROVED SYNCHRONIZATION MODULATION ELECTRIC FIELD) IN A PRECLINICAL ANIMAL MODEL USING ADULT YORKSHIRE PIGS WITH KIDNEY AUTOTRANSPLANTATION; AND 2) DETERMINE THE OPTIMAL PARAMETERS OF THE I-SMEF IN PROTECTION AGAINST ISCHEMIC INJURY OF THE DONOR KIDNEYS DURING COLD STORAGE AND IMPROVEMENT OF THE TRANSPLANTED GRAFT FUNCTION. IN THE PHASE I PROPOSAL, WE HAVE DEVELOPED A NOVEL TECHNIQUE, NAMED I-SMEF (PATENT PENDING). THE I-SMEF NOT ONLY CONTROLS THE NA/K PUMP ACTIVITY, BUT ALSO GENERATES ATP MOLECULES. BRIEFLY, BY UTILIZING THE INTRINSIC DUAL ENERGY TRANSFORM FUNCTIONS OF THE NA/K PUMPS, WE SPECIALLY DESIGNED THE I-SMEF TO CONTROL NA/K PUMP ACTIVITY. MEANWHILE, THE ELECTRIC FIELD PROVIDES ADEQUATE ENERGY TO THE PUMP MOLECULES SO THAT THEY CAN SYNTHESIZE ONE ATP MOLECULE FOR EACH PUMPING CYCLE. CONSEQUENTLY, THE I-SMEF CAN MAINTAIN THE NA/K PUMPING ACTIVITY IN SITUATIONS WITH AN INSUFFICIENT OR LACK OF ATP SUPPLY, SUCH AS IN HYPOXIA. THEN, WE DEMONSTRATED THAT THE APPLICATION OF THE I-SMEF ON THE DONOR KIDNEYS EFFECTIVELY PROTECTED TRANSPLANTED GRAFT FUNCTIONS IN A MOUSE KIDNEY TRANSPLANTATION MODEL. THESE DATA HAVE JUST BEEN PUBLISHED IN SCIENCE TRANSLATIONAL MEDICINE. IN THIS PHASE II PROPOSAL, WE WILL EXAMINE THE TRANSLATIONAL SIGNIFICANCE OF THE I-SMEF BY USING A PRECLINICAL PORCINE MODEL IN ADULT YORKSHIRE PIGS. TO MINIMIZE THE IMMUNORESPONSE AND FOCUS ON THE ISCHEMIA REPERFUSION INJURY, WE WILL USE KIDNEY AUTOTRANSPLANTATION MODEL. THEN, WE WILL DETERMINE THE OPTIMAL PARAMETERS, INCLUDING THE NUMBERS OF ELECTRODE PAIRS, FREQUENCY, AND VOLTAGE. CONSIDERING THE HIGH SIMILARITIES IN SIZE, ANATOMY AND PHYSIOLOGY BETWEEN HUMAN AND ADULT PIG KIDNEYS, WE BELIEVE THAT THE OPTIMAL PARAMETERS OBTAINED FROM PIGS ARE READILY APPLICABLE TO HUMANS IN THE PHASE III PROPOSAL.

Posted 9/16/22, 12:00 AM